0001171843-24-000112.txt : 20240108 0001171843-24-000112.hdr.sgml : 20240108 20240108070239 ACCESSION NUMBER: 0001171843-24-000112 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240105 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 24518282 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 8-K 1 f8k_010824.htm FORM 8-K Form 8-K
0000882796 False 0000882796 2024-01-05 2024-01-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 5, 2024

_______________________________

BioCryst Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware000-2318662-1413174
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockBCRXNasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

On January 5, 2024, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year ended December 31, 2023. The Company also provided guidance for full year 2024 ORLADEYO net revenue, full year 2024 operating expenses, expected peak ORLADEYO sales and an accelerated path to profitability. The press release also referenced a previously announced, upcoming webcast presentation by the Company at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 9, 2024 at 6:00 p.m. ET. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

Effective January 8, 2024, the Company is implementing an increase in the wholesale acquisition cost (WAC) for ORLADEYO in the United States from $40,348.60 per 28-day pack (of either 150mg or 110mg capsules) to $42,366.03 per 28-day pack (of either 150mg or 110mg capsules).

The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 BioCryst Pharmaceuticals, Inc.
   
  
Date: January 8, 2024By: /s/ Alane Barnes        
  Alane Barnes
  Chief Legal Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

—ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)—

—ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for
$1 billion in peak sales—

—Operating expenses expected to remain flat ($365-$375 million) in 2024—

—Company expects operating profit in 2024, approaching positive EPS and positive cash flow in 2H 2025—

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year 2023. The company also provided guidance for full year 2024 ORLADEYO net revenue, full year 2024 operating expenses, expected peak ORLADEYO sales and an accelerated path to profitability.

“After three years on the market, ORLADEYO continues on a steady growth trajectory to achieve $1 billion at peak. This commercial success, alongside our proven discovery platform that is producing additional first-in-class or best-in-class molecules, uniquely positions BioCryst to achieve financial independence from the capital markets and accelerate our path to profitability,” said Jon Stonehouse, president and chief executive officer of BioCryst.

The company also announced that, if its ongoing proof-of-concept trial produces best-in-class data, it plans to out-license late-stage development and commercialization of BCX10013, its potential once-daily, oral Factor D inhibitor, to a partner that can drive the speed and breadth of investment required to accelerate BCX10013 for patients across multiple complement-mediated diseases and maximize the commercial potential of the program. As a result, the company has reduced the size of its R&D organization and accelerated its timeline to profitability.

Preliminary Fourth Quarter and Full Year 2023 ORLADEYO Revenue and 2024 ORLADEYO Outlook
Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2023 was $89.9 million (+27 percent y-o-y). Preliminary, unaudited ORLADEYO net revenue for full year 2023 was $325 million (+29 percent y-o-y).

The company expects full year 2024 global net ORLADEYO revenue to be between $380 million and $400 million. The general pattern of revenue throughout 2024 is expected to be similar to past years, with the seasonal impact of prescription reauthorizations and the potential impact of the Inflation Reduction Act in the first quarter driving a quarter-over-quarter revenue decline in the first quarter, followed by a strong return to growth in the second quarter.

“ORLADEYO growth remained strong in the fourth quarter of 2023 as hereditary angioedema patients gain the excellent attack control they expect. Comparing U.S. patient trends year over year (y-o-y), we had more new patient prescriptions and a lower average rate of monthly discontinuations in 2023 compared to 2022. U.S. performance combined with continued global expansion keep ORLADEYO on track for $1 billion in peak sales,” said Charlie Gayer, chief commercial officer of BioCryst.

Operating Expense and Profitability Outlook
The company expects full year 2024 operating expenses to be between $365 million and $375 million, flat to expected full year 2023 operating expenses. The company now expects that R&D expenses in 2024 will be reduced by $20 million versus 2023. This represents a $45 million to $55 million reduction from the 2024 R&D expense guidance it provided at its R&D Day in November 2023, and reflects both the R&D restructuring and the postponement of previously planned capital expenditures at its Discovery Center in Alabama. SG&A expenses are expected to increase by $20 million in 2024, primarily to support the continued U.S. and global growth of ORLADEYO to $1 billion in peak sales.

This operating expense outlook does not reflect non-cash stock compensation expense, or one-time expenses related to the reduction of 59 jobs (10 percent of total organization) in the first quarter of 2024.

Based on the company’s disciplined approach to capital allocation, and the revenue expected from ORLADEYO, the company expects to achieve a full-year operating profit in 2024 (not including non-cash stock compensation), be approaching quarterly positive earnings per share (EPS) and positive cash flow in the second half of 2025 (not including non-cash stock compensation), and be profitable on an EPS basis, with positive cash flow, for full year 2026. The company expects it can achieve these financial milestones without raising additional funds and does not intend to draw the additional $150 million of debt available to it from Pharmakon.

Presentation Tuesday at 42nd Annual J.P. Morgan Healthcare Conference
On Tuesday, January 9, 2024 at 6:00 p.m. ET, the company will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at https://www.biocryst.com/.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding preliminary, unaudited net revenue results and future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any preliminary, unaudited net revenue results and future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s completion of its customary closing, review and audit procedures for the fourth quarter and full year 2023, which may cause actual net revenue results for these periods to differ materially from the preliminary, unaudited revenue results; the ongoing COVID-19 pandemic, which could create challenges in all aspects of BioCryst’s business, including without limitation delays, stoppages, difficulties and increased expenses with respect to BioCryst’s and its partners’ development, regulatory processes and supply chains, negatively impact BioCryst’s ability to access the capital or credit markets to finance its operations, or have the effect of heightening many of the risks described below or in the documents BioCryst files periodically with the Securities and Exchange Commission; BioCryst’s ability to successfully implement its commercialization plans for, and to commercialize, ORLADEYO, which could take longer or be more expensive than planned; BioCryst’s ability to successfully implement its plans for BCX10013, including any out-licensing of late-stage development and commercialization of BCX10013 as described herein; risks related to the reduction in size of BioCryst’s R&D organization; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve market acceptance; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; timing for achieving profitability and positive cash flow may not meet management’s expectations; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

 

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 05, 2024
Entity File Number 000-23186
Entity Registrant Name BioCryst Pharmaceuticals, Inc.
Entity Central Index Key 0000882796
Entity Tax Identification Number 62-1413174
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4505 Emperor Blvd., Suite 200
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27703
City Area Code 919
Local Phone Number 859-1302
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol BCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 f8k_010824_htm.xml IDEA: XBRL DOCUMENT 0000882796 2024-01-05 2024-01-05 iso4217:USD shares iso4217:USD shares 0000882796 false 8-K 2024-01-05 BioCryst Pharmaceuticals, Inc. DE 000-23186 62-1413174 4505 Emperor Blvd., Suite 200 Durham NC 27703 919 859-1302 false false false false Common Stock BCRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_010824.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_010824.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_010824.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_010824.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_010824.htm", "first": true, "unique": true } } }, "tag": { "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001171843-24-000112-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-000112-xbrl.zip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